Pneumococcal serotypes causing pneumonia with pleural effusion in pediatric patients

Running title: Pneumococcal serotypes and pleural effusions

Authors: Jigui Yu\textsuperscript{1}, Douglas Salamon \textsuperscript{2}, Mario Marcon \textsuperscript{2,3}, Moon H. Nahm \textsuperscript{1*}

\textsuperscript{1} Department of Pathology, University of Alabama at Birmingham, Birmingham, AL,
\textsuperscript{2} Department of Laboratory Medicine, Nationwide Children’s Hospital, Columbus, OH.
\textsuperscript{3} Departments of Pediatrics and Pathology, Ohio State University, College of Medicine and Public Health, Columbus, OH.

Corresponding Author:
Moon H. Nahm, M.D.
University of Alabama at Birmingham
BBRB 614
1530 Third Avenue South
Birmingham, AL 35294-2170
Phone: 205-934-0163
Fax: 205-975-5479
Email: nahm@uab.edu
Abstract

To determine the prevalence of serotypes of *Streptococcus pneumoniae* responsible for pneumonia with pleural effusion, we determined the capsular polysaccharide (PS) type directly on 49 pleural fluid specimens collected from pediatric patients during 2007-2009 with laboratory-confirmed pneumococcal pneumonia using monoclonal antibodies and a multiplex, bead-array immunoassay. Because the fluids had to be heated to remove nonspecific reactivity before testing in the immunoassay and type 19A PS is heat labile, the pleural fluid samples were also tested for serotype 19A capsule gene locus by PCR. Use of the multiplex immunoassay combined with type-specific 19A PCR allowed for serotype determination on 40 of 49 pleural fluids. Pneumococcal pneumonia with pleural effusion was associated with a limited number of serotypes with types 1, 3, 7F/A, and 19A accounting for 75% of the typeable cases. The concentration of capsular PS in the pleural fluids was often greater than 1 ug/mL and sufficient to inhibit opsonic capacity of sera from individuals who had received the 23-valent pneumococcal PS vaccine. Based on the serotypes observed before and after introduction of the 7-valent pneumococcal conjugate vaccine, the recently licensed 13-valent pneumococcal conjugate vaccine may reduce the incidence of pneumonia with pleural effusions.
Introduction

Parapneumonic pleural effusions in children are most commonly associated with pneumococcal infections, and they may lead to the more serious complication of empyema (10). With the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in 2000, there has been a dramatic decrease in the number of cases of invasive pneumococcal disease (IPD) in the USA; however, the incidence of empyema has actually increased by as much as 50% (6). To investigate the apparent failure of PCV7 in reducing the incidence of pneumonia with empyema, it is important to investigate pneumococcal serotypes associated with parapneumonic pleural effusions obtained after PCV7 became widely used.

While pneumococcal serotypes associated with pleural effusions have been studied in the past (6), most studies used pneumococcal isolates obtained from blood or pleural fluid cultures of patients; however, this approach is insensitive and may preferentially recover antibiotic resistant serotypes because most patients are treated with antibiotics and only a small percentage of cases yield positive cultures. To avoid these limitations, two reports investigated pleural fluids directly for the presence of pneumococcal capsular PS with monoclonal antibodies (10, 12); however, these studies were performed in England before PCV7 was widely used and they tested the fluids for only 13 capsular PS serotypes.

Recently, we developed a multiplex immunoassay to detect capsular PS of 36 pneumococcal serotypes on cultured isolates (29). The method was...
modified to detect and quantify the concentration of capsular PS directly in clinical samples such as pleural fluids. We used this modified method to identify pneumococcal serotypes in pleural fluids recently collected from a pediatric population in central Ohio, a geographic region where PCV7 is widely used to immunize children.

Materials and Methods

Pleural fluid Specimens

Pleural fluid specimens examined in this study were obtained from children admitted to Nationwide Children's Hospital, Columbus, Ohio from 2007-2009 with suspected bacterial pneumonia and in whom pleural fluid was obtained as per standard of care by thoracentesis with or without chest tube placement. A laboratory diagnosis of pneumococcal pneumonia was made based on a positive blood or pleural fluid culture or a positive PCR on pleural fluid for both the pneumococcal autolysin and pneumolysin genes (ICAAC 2009, Abst. #D-780; manuscript in preparation). Residual pleural fluid samples were stored at -70°C. A total of 49 positive samples from 49 children ages 0.4 to 15 yr (median 4 yr) were removed from storage, coded so as to remove patient identifiers, and sent to University of Alabama at Birmingham for serotype analysis. This study was approved by Nationwide Children’s Hospital Institutional Review Board.

Multiplex Immunoassay for Capsular Polysaccharide

Pleural fluid samples were brought to 0.05 M EDTA and the mixtures were boiled for 10 min (19, 22), diluted 1:10 and 1:30, and subjected to a latex bead-
based, multiplexed immunoassay for pneumococcal PS types using a
modification of a previously described procedure for typing of culture isolates
(29). Briefly, latex bead sets treated with various red colored dyes recognizable
by their differential fluorescence signal were coated with type-specific
pneumococcal capsular PS and mixed with PS-specific monoclonal antibodies
and pleural fluid samples. Free PS in the pleural fluid sample binds to free PS-
specific monoclonal antibody and thus competitively inhibits specific binding of
the free monoclonal antibody to the latex beads coated with the specific PS.
Presence of type specific PS in the pleural fluid was determined by flow
cytometry by observing for a reduction in fluorescence signal after washing of the
beads and addition of phycoerythrin-conjugated anti-mouse immunoglobulin
antibody. The assay has been designed to identify pneumococcal capsular PS
of 36 serotypes including all those in the 23-valent pneumococcal PS vaccine.
To determine capsular PS concentrations in 15 pleural fluid samples, eight
3-fold serial dilutions of the 15 samples and purified PS controls containing 1
µg/ml of purified capsular PS were prepared. The PS controls were purchased
from ATCC (Manassas, VA) and included serotypes 1, 3, 6B, 7F, 8, 19A, and
33F. The diluted samples and controls were then subjected to the multiplexed
immunoassay and the capsular PS concentrations in the pleural fluids were
determined by comparing the fluorescence signals of the samples at different
dilutions to that of the standard curves constructed with the PS controls.

**Multiplex Opsono-phagocytosis Assay**
To obtain an antibiotic-free pleural fluid, 100 µl of a pleural fluid sample containing serotype 3 PS (~20 µg/ml) was loaded into a 250 µl G-25-80 column. The column was eluted with normal saline and the eluate was collected in 35 µL fractions. The fractions were tested for antibiotic activity and the presence of serotype 3 PS. Fractions that were free of antibiotics, but with type 3 PS levels equivalent to the level in the original pleural fluid, were pooled and used in opsono-phagocytosis assays.

The antibiotic-free, serotype 3 containing pleural fluid and a serotype 3 purified PS solution (10 µg/ml) were then separately mixed with an equal volume of a post-pneumococcal vaccination serum pool. The serum pool was prepared by mixing serum from 2 adults previously immunized with a 23-valent PS vaccine. The serum pool and pleural fluid alone, as well as and serum pool/type-3 pleural fluid or serum pool/type-3 purified PS mixtures were analyzed for their capacity to opsonize pneumococci in a multiplexed opsono-phagocytosis assay using the HL60 human cell line as phagocytic cells, baby rabbit serum as a source of complement, and OREP3 and STREP8 as target pneumococcal strains (5, 21). OREP3 is an optochin resistant pneumococcal strain expressing serotype 3 PS and STREP8 is a streptomycin resistant strain expressing serotype 8 PS. The opsonic index was defined as the serum dilution that killed 50% of target bacteria.

**PCR for Pneumococcal Serotype 19A**

To identify the 19A-specific capsular gene, bacterial lysates or pleural fluid samples were diluted 10-fold in water and subjected to 2 PCRs – one targeting...
the pneumococcal wzy, the other the cpsA gene - using previously described assay conditions (18). The primers targeting the pneumococcal wzy gene were specific for the 19A serotype and the primers targeting the cpsA gene were specific for all pneumococcal capsular PS genes and used as a positive control. The reaction products were separated by agarose electrophoresis, stained with ethidium bromide, and visualized under UV light.

Results

Determination of pneumococcal serotypes in pleural fluids

When the 49 pleural samples were directly analyzed for capsular PS with a multiplexed immunoassay, serotypes could be identified for 36 samples (Table 1). The most common serotype was serotype 3, accounting for 13 samples, and the next most common serotypes were 1, 7F, and 19A, accounting for six, seven, and seven samples, respectively. Pneumococci were isolated from pleural fluids of 5 patients and the serotypes of the isolates matched the serotypes identified by testing the pleural fluids directly (Table 1). The immunoassay could not identify the serotypes of 13 pleural fluid samples. Since our immunoassay tests for 36 serotypes, the 13 samples may express one of the remaining 57 serotypes that were not included in our multiplex immunoassay. Alternatively they may contain PS below the limits of detection of our immunoassay.

While investigating the limits of detection of the immunoassay, we found that unlike other pneumococcal PS types tested, type 19A PS is heat-labile. A 10 min. boiling reduced the immunoreactive concentration of purified 19A PS to
less than 0.1% of the original concentration (Figure 1). Following this discovery, the pleural fluid samples were re-examined for the presence of capsule gene locus of 19A serotype by PCR (18). The PCR test confirmed that all 7 samples previously identified to be 19A and 4 previously non-typeable samples had DNA for 19A capsule gene locus (data not shown).

**Quantification of pneumococcal capsular PS in the pleural fluids**

To determine the PS concentrations in pleural fluids, we selected 15 samples and re-analyzed them without boiling using standard curves constituted with purified pneumococcal PS. Two samples had only about 0.1 µg/ml of capsular PS; however, 7 samples had capsular PS concentrations between 1-10 µg/ml, 6 samples had >10 µg/ml, and one serotype 3 sample had 800 µg/ml of PS (Table 2).

**Effect of capsular PS in pleural fluids on opsono-phagocytosis**

About 0.1 to 1 µg/ml of capsular PS was shown to inhibit opsono-phagocytic capacity of post-immune sera from many vaccine recipients (15, unpublished data). Since most pleural fluids had more than 1 µg/ml of capsular PS (Table 2), we hypothesized that pleural fluids could inhibit opsonic capacity of immune sera. To directly test this possibility, we selected a serotype 3 pleural fluid sample containing 20 µg/ml PS and of sufficient volume to allow for additional testing. Because this sample, similar to other pleural fluids, contained antibiotics and was bactericidal (data not shown), it was subjected to column chromatography as described to remove the antibiotics. When the antibiotic-free pleural fluid containing type 3 pneumococcal PS was mixed with an immune
serum pool with a high opsonic index against both serotypes 3 and 8, the opsonic index to serotype 3 was almost completely neutralized while that of serotype 8 was not (Figure 2). The opsonic index of the serum pool to serotypes 3 could be completely neutralized with 5 µg/ml of capsular PS of serotype 3 (Left Panel). Thus, the pleural fluids of patients with pleural effusions have sufficient capsular PS to neutralize type-specific anti-capsular antibodies in vitro.

Discussion

Previous studies have shown that pneumococcal pneumonia with pleural effusion is associated with a limited number of serotypes. Table 3 summarizes 9 published studies of pneumococcal pneumonia with pleural effusion and lists the five most common pneumococcal serotypes isolated in culture. It is possible that these serotype prevalence studies based on typing of culture isolates may be biased toward serotypes that express antibiotic resistance and thus be more likely to be recovered in culture. This is because many patients with suspected community-acquired pneumonia are treated as outpatients with oral antibiotics. Amoxicillin alone or in combination with azithromycin is commonly used to manage pediatric patients without severe pneumonia and without underlying disease. Of those patients who fail oral outpatient therapy and go on to develop pleural effusion and require hospitalization, only a small percentage, typically 10-20% in most studies, yield culture isolates. There are reported differences in antibiotic resistance among serotypes.

With our combination of multiplex immunoassay and 19A PCR directly on pleural fluid, we were able to determine the serotype in 40 of 49 (82%) cases of pneumococcal pneumonia with pleural effusion. The 4 most common serotypes in our study.
accounting for 75% of typable cases, were serotypes 1, 3, 7F and 19A. We cannot draw conclusions on how the 9 non-typable pleural fluids might have impacted the serotype distribution in our study. Notwithstanding, these same 4 serotypes were also found to be common in another recent study of pneumococcal pneumonia (Table 3) (6), but not all were commonly represented in studies where samples were collected before 2001 (Table 3). These observations suggest that serotype prevalence data based on testing of culture isolates may not be biased toward isolates that express antibiotic resistance. Furthermore, all 5 of the culture positive isolates in our study were very susceptible to the beta-lactam agents tested including penicillin, amoxicillin, and ceftriaxone with MICs in the 0.01 to 0.04 ug/mL range. Four of five isolates were also susceptible to erythromycin with MICs of 0.12 ug/mL. Clearly, other factors such as dose and length of oral antibiotic therapy, host immune response, and virulence of the serotype are clearly important in determining which patients develop effusion and which have positive cultures.

The multiplexed immunoassay for typing of pneumococcal PS in pleural fluids required heat pre-treatment to remove interfering substances; however, during this processing, we discovered that 19A PS is quite heat-labile whereas other PS types, including 19F, are heat-stable. This selective heat lability is interesting since 19A and 19F PS are structurally very similar and a previous study noted both 19A and 19F PS were heat-labile (25). Of note is that 6A and 6B PS are very similar in structure, but differ in hydrolytic stability (4, 30). It is possible that only the epitope recognized with the 19A specific monoclonal antibody used in our assay is heat-labile and the heat lability may not be observed with a different 19A-specific monoclonal antibody. Additional studies are being performed to investigate these possibilities. Heat pre-treatment is
widely used to reduce interfering substances in serum or urine samples before subjecting them to immunoassay (9, 19, 22, 23) and one should be aware that heating may reduce the apparent concentration of certain pneumococcal capsule types.

We also found that the level of capsular PS in pleural fluid is generally greater than 1 µg/ml, which is sufficient to neutralize the opsonic capacity of anti-capsular antibodies in vitro. It is possible that free pneumococcal capsular PS in pleural effusions in vivo can neutralize type-specific anti-capsular antibodies and thus promote the replication of pneumococci. Neutralization of opsonic capacity by free capsular PS may be an important mechanism of pathogenesis of pleural effusion and progression to empyema. This mechanism may also apply to infections involving limited tissue spaces such as otitis media and it should be interesting to determine the concentration of capsular PS found in ear fluids from patients with otitis media.

Pleural effusion is a complication of pneumococcal pneumonia and serotype prevalence among cases of pleural effusions may reflect serotype prevalence in all cases of pneumococcal pneumonia. We believe that serotype 7F and 19A may be such serotypes. These two serotypes have become more common among cases of IPD following the use of PCV7 as a part of a general shift of serotypes (1, 14, 16). Also, these serotypes have become noticeable among studies of pneumococcal pneumonia with empyema performed in the post-PCV7 era, but not among studies performed before introduction of PCV7 (Table 3). Interestingly, serotype 14 was very common, accounting for 12-29%...
of cases in 6 separate studies before introduction of PCV7 (Table 3), but it has
not been observed in three studies performed after introduction of PCV7 (6).

Similarly, none of the pleural fluid samples collected in the 2007-2009 time period
of our study were serotype 14. These data suggest that PCV7 has been effective
in preventing pneumonia with pleural effusions due to serotype 14 pneumococci.

PCV7 does not contain serotypes 1 and 3 and it would not have affected
their prevalence; however, the incidence of pneumonia with pleural effusions
associated with serotypes 1 and 3 has been disproportionately high compared to
their pneumonia incidence in many studies (Table 3) (11, 24). Serotype 3 has
been known to produce high levels of capsule and the level of capsular PS may
be important in pathogenesis of pneumonia with pleural effusions as discussed.

Perhaps serotype 3 pneumococci are prone to causing pleural effusions because
they can produce high and protective concentrations of capsular PS, overcome
host immunity, and proliferate better than other pneumococcal serotypes.

Interestingly, prevalence of serotype 3 is disproportionately higher in otitis media
than in IPD in many different geographic regions (20). Perhaps the pleural cavity
and the middle ear are body cavities conducive for the high capsule producing
serotypes.

Serotype 1 pneumococcus has been an uncommon (only 1-2%) cause of
IPD since the 1960’s (11). Yet it is the primary serotype associated with
empyema, accounting for 21-67% for 9 studies done in several countries from
1993 until 2007 (Table 3). One may be able to understand this remarkable
clinical observation with recent discoveries of immunological properties of
zwitterionic PS (2, 8). Zwitterionic PS has both positive and negative charges in its repeating unit whereas most bacterial capsular PS have either only neutral or negative charges. Serotype 1 PS is zwitterionic since its repeating unit has one positively charged amino group and two negatively charged groups and it has been shown to stimulate T cells (28) and induce intra-abdominal abscess in animal models (27). Induction of abdominal abscess was not unique to serotype 1 PS because zwitterionic PSs from other bacteria can induce abscess formation (27). These biological properties would permit serotype 1 pneumococci to form abscesses and to enhance development of empyema. In fact, serotype 1 has been clinically associated with complicated clinical presentations among empyema cases (26).

While PCV7 appears to have been effective in reducing empyema by serotype 14, our study confirms that PCV7 would be inadequate against current cases of pneumococcal empyema since the vaccine does not cover against the serotypes responsible for the majority of cases. Since the recently approved PCV13 includes the four main detected serotypes causing pleural effusions, 1, 3, 7F, and 19A, it may be useful in reducing the incidence of pneumococcal empyema. Future studies should be done to monitor the effect of the new vaccine on empyema among children.
Acknowledgments

The work was supported by Public Health Service grant AI-31473 from the National Institutes of Health to MHN.


Table 1: Pneumococcal serotypes of 49 cases of pneumonia with pleural effusion as determined by multiplex immunoassay directly on pleural fluids

<table>
<thead>
<tr>
<th>Serotype</th>
<th>No. Positive</th>
<th>No. confirmed by isolation of S. pneumoniae from pleural fluid**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>13</td>
<td>2</td>
</tr>
<tr>
<td>19A</td>
<td>11 (7+4)*</td>
<td></td>
</tr>
<tr>
<td>7F/A</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>1</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>6B</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>8</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>33F/A</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Non-typeable</td>
<td>9 (13-4)*</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>49</td>
<td></td>
</tr>
</tbody>
</table>

* Four samples contained non-detectable amount of capsular PS but were found to contain DNA of serotype 19A capsule synthesis gene locus by PCR.

** Serotyping results of all 5 available isolates agreed with direct typing results of pleural fluids.
**Table 2:** Concentration of pneumococcal PS in 15 pleural fluids of patient with pneumococcal pneumonia with effusion

<table>
<thead>
<tr>
<th>Sample</th>
<th>Serotype</th>
<th>PS Concentration (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3</td>
<td>0.1</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>0.1</td>
</tr>
<tr>
<td>3</td>
<td>3</td>
<td>1.0</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>1.0</td>
</tr>
<tr>
<td>5</td>
<td>7F</td>
<td>1.0</td>
</tr>
<tr>
<td>6</td>
<td>7F</td>
<td>1.0</td>
</tr>
<tr>
<td>7</td>
<td>19A*</td>
<td>1.0</td>
</tr>
<tr>
<td>8</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>9</td>
<td>7F</td>
<td>8</td>
</tr>
<tr>
<td>10</td>
<td>19A*</td>
<td>19</td>
</tr>
<tr>
<td>11</td>
<td>3</td>
<td>20</td>
</tr>
<tr>
<td>12</td>
<td>7F</td>
<td>33</td>
</tr>
<tr>
<td>13</td>
<td>19A*</td>
<td>79</td>
</tr>
<tr>
<td>14</td>
<td>1</td>
<td>90</td>
</tr>
<tr>
<td>15</td>
<td>3</td>
<td>800</td>
</tr>
</tbody>
</table>

* Concentrations of 19A PS were determined with samples that were not heat pretreated.
Table 3: Summary of 11 published reports showing the five most prevalent pneumococcal serotypes isolated from pleural effusions

<table>
<thead>
<tr>
<th>No. of samples</th>
<th>Collection Date (Year)</th>
<th>No.1</th>
<th>No.2</th>
<th>No.3</th>
<th>No.4</th>
<th>No.5</th>
<th>Sum (%)</th>
<th>Location of study</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>1975-1978</td>
<td>1</td>
<td>3</td>
<td>7F</td>
<td>X</td>
<td>X</td>
<td>100</td>
<td>Pennsylvania</td>
<td>(24)</td>
</tr>
<tr>
<td>26</td>
<td>1993-1999</td>
<td>1</td>
<td>14</td>
<td>9V</td>
<td>19F</td>
<td>18C</td>
<td>88.5</td>
<td>Utah</td>
<td>(6)</td>
</tr>
<tr>
<td>133</td>
<td>1993-2000</td>
<td>14</td>
<td>1</td>
<td>19</td>
<td>3</td>
<td>6</td>
<td>88.5</td>
<td>US Multicenter</td>
<td>(26)</td>
</tr>
<tr>
<td>24</td>
<td>1996-2000</td>
<td>1</td>
<td>14</td>
<td>6B</td>
<td>19F</td>
<td>6A</td>
<td>79.3</td>
<td>Utah</td>
<td>(7)</td>
</tr>
<tr>
<td>27</td>
<td>1997-2001</td>
<td>1</td>
<td>14</td>
<td>3</td>
<td>X</td>
<td>X</td>
<td>78.1*</td>
<td>UK</td>
<td>(10)</td>
</tr>
<tr>
<td>11</td>
<td>1990-2002</td>
<td>1</td>
<td>4</td>
<td>5</td>
<td>X</td>
<td>X</td>
<td>100.0</td>
<td>Israel</td>
<td>(13)</td>
</tr>
<tr>
<td>35</td>
<td>2000-2003</td>
<td>14</td>
<td>3</td>
<td>1</td>
<td>6B</td>
<td>9V</td>
<td>84.2</td>
<td>Canada</td>
<td>(17)</td>
</tr>
<tr>
<td>30</td>
<td>2002-2004</td>
<td>19A</td>
<td>1</td>
<td>14</td>
<td>3</td>
<td>23F</td>
<td>100.0</td>
<td>France</td>
<td>(3)</td>
</tr>
<tr>
<td>27</td>
<td>2003-2004</td>
<td>1</td>
<td>4</td>
<td>3</td>
<td>7F</td>
<td>9V</td>
<td>92.6</td>
<td>UK</td>
<td>(12)</td>
</tr>
<tr>
<td>50</td>
<td>2001-2005</td>
<td>1</td>
<td>3</td>
<td>19A</td>
<td>19F</td>
<td>7</td>
<td>78.0</td>
<td>Utah</td>
<td>(7)</td>
</tr>
<tr>
<td>51</td>
<td>2001-2007</td>
<td>1</td>
<td>3</td>
<td>19A</td>
<td>7F</td>
<td>17</td>
<td>92.2</td>
<td>Utah</td>
<td>(6)</td>
</tr>
</tbody>
</table>

"X" indicates absence of reported serotypes.
* 11.9 % (3 samples) were negative for the 13 serotypes tested.
Figure 1: Residual pneumococcal capsular PS (Y-axis) activity of various PS types (X-axis) as determined by a multiplex immunoassay after heat treatment. Heat treatment involved boiling purified PS samples for 10 min with 0.05 M EDTA. PSs were obtained from ATCC.

Figure 2: Opsonic index (Y-axis) of a post-pneumococcal vaccine serum pool against a serotype 3 (left panel) and serotype 8 (right panel) pneumococcal isolate in different sample mixtures. The serum pool had high opsonic activity to both serotypes 3 and 8. Pleural fluid containing serotype 3 PS and purified type 3 PS (5 µg/ml) was used in all experiments.
Serotype 3

<table>
<thead>
<tr>
<th>Opsonic Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
</tr>
</tbody>
</table>

Pleural Fluid (type 3) + - + -
Serum Pool - + + +
Type 3 PS - - - +

Serotype 8

<table>
<thead>
<tr>
<th>Opsonic Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
</tr>
</tbody>
</table>

+ - + -
- + + +
- - - +
- - - +